Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481128 | 0.82 | CYP3A4 (0.82) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL18381359 | 0.81 | TBXAS1 (0.62) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| Carcinine SCHEMBL19051459 | 0.80 | TSHR (1.00) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL18381205 | 0.80 | CYP3A4 (0.74) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL17483163 | 0.80 | CYP3A4 (0.78) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL17481134 | 0.80 | CYP3A4 (0.78) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL18381401 | 0.80 | TBXAS1 (0.65) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL21794919 | 0.79 | NLN (0.67) | MEN1KMT2ACYP3A4CYP2D6TSHR | |
| SCHEMBL7758645 | 0.79 | MEN1 (0.60) | MEN1KMT2A | |
| Carcinine SCHEMBL20528864 | 0.79 | LMNA (1.00) | MEN1KMT2ACYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |